BUSINESS Jubilant Pharmova to transfer unclaimed dividends and shares to IEPF by October 2026 Mar 30, 2026
CORPORATES Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Proprietary novel drugs business Dec 2, 2025
CORPORATES Jubilant Pharmova receives 4 observations from USFDA after Pre-Approval Inspection at Roorkee facility Aug 2, 2025